Patent intelligence · US
US 10983128
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
Patent details — US 10983128
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 20, 2021
- Expiration
- Apr 15, 2041
- Applicant
- Providence Health & Services
- Claims
- 16
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545
Quick answer
US 10983128 (CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy) is held by Providence Health & Services. Status: granted. Granted Apr 20, 2021. Expires Apr 15, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Providence Health & Services
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K2039/55, A61K39/39558
More from Providence Health & Services
Related pharmaceutical patents in our USPTO index.
-
US 12364708
Injectable scaffold for treatment of intracranial aneurysms and related technology
granted -
US 12358968
Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer
granted -
US 12336973
Cancer therapeutic compositions and methods targeting DNAse1L3
granted -
US 12329909
Airway management systems for pulmonary disorder treatment
granted -
US 12285397
Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
granted -
US 12185909
System and method for cleansing segments of a luminal network
granted -
US 12150461
Nicotinamide adenine dinucleotide (NAD) compositions, methods of manufacturing thereof, and methods of use thereof
granted -
US 12144801
Methods and compositions for treatment of epileptic disorders
granted
Frequently asked questions
What is US patent 10983128?
US 10983128 (CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy) is held by Providence Health & Services. Status: granted. Granted Apr 20, 2021. Expires Apr 15, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10983128?
Providence Health & Services is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 193 pharmaceutical patents for this assignee.
When does US 10983128 expire?
Our index shows an expiration date of Apr 15, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.